Abstract
A new method of biochemical modulation of 5‐fluorouracil (5‐FU) with 3‐azido‐3′‐deoxythymidine (AZT)was studied experimentally. Nude mice transplanted with cells of the human gastric cancer cell line MKN28 were divided into 4 groups, i.e., control, 5‐FU, AZT, and 5‐FU plus AZT, and the antitumor activities were compared. Based on the assessment of tumor volume, significant suppression of tumor growth was observed in the 5‐FU and 5‐FU plus AZT groups (P<0.05, P<0.01, versus control, respectively). The thymidylate synthase (TS) inhibition rate, an index of inhibition of the de novo pathway, was significantly higher in the 5‐FU and 5‐FU plus AZT groups than in the control group (P<0.01), but it did not differ from the control in the AZT group. TS‐bound FdUMP tended to be higher in the 5‐FU pins AZT group than in the 5‐FU group. The activity of thymidine kinase (TK) and the uptake ratio of 5‐hromo‐2′‐deoxyuridine (BrdU), indices of salvage pathway activity, were significantly lower in the AZT and 5‐FU plus AZT groups than in the control group (TK, P<0.05, P< 0.01; uptake ratio of BrdU, P< 0.01, P< 0.05, respectively). There were slight losses of body weight in the 5‐FU and 5‐FU plus AZT groups compared with that in the control group, but no difference between the AZT and control groups in weight loss. These findings suggest that addition of AZT plays an important role in potentiating the antitumor activity of 5‐FU through both blockage of a compensatory increase of activity in the salvage pathway and also an increase in TS‐bound FdUMP, anid has no adverse effects. Thus, the combination of 5‐FU and AZT could be useful as a new modality in gastric cancer chemotherapy.
Keywords: Biochemical modulation, 3‐Azido‐3 deoxythymidine, 5‐Fluorouracil, Gastric cancer, Prevention of DNA synthesis
Full Text
The Full Text of this article is available as a PDF (374.2 KB).
REFERENCES
- 1. ) Petrelli , N.J. , Madajewicz , S. , Herrera , L. , Rustum , Y. M. , Trave , F. , Creaven , P. and Mittelman , A.Biologic modulation of 5‐fluorouraciI with high‐dose leucovorin and combinationchemotherapy of5‐fluorouracil and cisplatin in metastatic colorectal adenocarcinoma . Ned. Chem. Ind. Monogr. , 5 , 189 – 192 ( 1987. ). [PubMed] [Google Scholar]
- 2. ) Weber , G.Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture . Cancer Res. , 43 , 3466 – 3492 ( 1983. ). [PubMed] [Google Scholar]
- 3. ) Spiegelman , S. , Nayak , R. , Sawyer , R. , Stolfi , R. and Martin , D.Potentiation of the anti‐tumor activity of 5FU by thymidine and its correlation with the formation of (5FU) RNA . Cancer , 45 , 1129 – 1134 ( 1980. ). [DOI] [PubMed] [Google Scholar]
- 4. ) Brunetti , I. , Falcone , A. , Calabresi , P. , Goulette , F. A. and Darnowski , J. W.5‐Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies . Cancer Res. , 50 , 4026 – 4031 ( 1990. ). [PubMed] [Google Scholar]
- 5. ) Unadkat , J. D. , Wang , J. P. , Pulham , D. and Semmes , R. L. O.Dose‐ranging pharmacokinetics of zidovudine (azidothymidine) in the rat . Pharm. Res. 6 , 734 – 736 ( 1989. ). [DOI] [PubMed] [Google Scholar]
- 6. ) Spears , C. P. , Shahinian , A. H. , Moran , R. G. , Heiderberger , C. and Corbett , T. H.In vivo kinetics of thymidylatesynthetaseinhibitionin5‐fluorouracil‐sensitive and ‐resistant murine colon adenocarcinomas . Cancer Res. , 42 , 450 – 456 ( 1982. ). [PubMed] [Google Scholar]
- 7. ) Taylor , A.Jr. , Hewitt , E. G. and Jones , O. W.Tumor‐associated thymidine kinase in the sera of rats with transplanted hepatomas . Cancer Res. , 36 , 2070 – 2072 ( 1976. ). [PubMed] [Google Scholar]
- 8. ) Masuike , T. , Watanabe , I. and Takemoto , Y.Quantitative method of 5‐fluorouracil and its metabolites in biological samples using high performance liquid chromatography , J. Pharm. Soc. Jpn. 105 , 1058 – 1064 ( 1985. ), in Japanese . [DOI] [PubMed] [Google Scholar]
- 9. ) Gratzner , H. G.Monoclonal antibody to 5‐bromo‐ and 5‐iododeoxyuridinei a new reagent for detection of DNA replication . Science , 218 , 474 – 475 ( 1982. ). [DOI] [PubMed] [Google Scholar]
- 10. ) Sasaki , K. , Ogino , T. and Takahashi , M.Immunological determination of labeling index on human tumor tissue sections using monoclonal anti‐BrdU antibody . Stain Technol. , 66 , 155 – 161 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 11. ) Scanlon , K. J. , Newman , E. M. , Lu , Y. and Priest , D. G.Biochemical basis for cisplatin and 5‐fluorouracil synergism in human ovarian carcinoma cells . Proc. Natl. Acad. Sci. USA , 83 , 8923 – 8925 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. ) Kish , J. , Drelichman , A. , Jacobs , J. , Hoschner , J. , Kinzie , J. , Loh , J. , Weaver , A.and Al‐Sarraf, M. Clinical trial of cisplatin and 5‐FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck . Cancer Treat. Rep. , 66 , 471 – 474 ( 1982. ). [PubMed] [Google Scholar]
- 13. ) Evans , R. M. , Laskin , J. D. and Hakala , M. T.Effect of excess folates and deoxyinosine on the activity and site of actionof5‐fluorouracil . Cancer Res. , 41 , 3288 – 3295 ( 1981. ). [PubMed] [Google Scholar]
- 14. ) Machover , D. , Goldschmidt , E. , Chollet , P. , Metzger , G. , Zittoun , J. , Marquet , J. , Vandenbulcke , J.‐M. , Misset , J.‐L. , Schwarzenberg , L. , Fourtillan , J. B. , Gaget , H. and Mathé , G.Treatment of advanced colorectal and gastric adenocarcinomas with 5‐fluorouracil and high‐dose folinic acid . J. Clin. OncoL , 4 , 685 – 696 ( 1986. ). [DOI] [PubMed] [Google Scholar]
- 15. ) Bertino , J. R. , Sawicki , W. L. , Lindquist , C. A. and Gupta , V. S.Schedule‐dependent antitumor effects of methotrexate and 5‐fluorouracil . Cancer Res. , 37 , 321 – 328 ( 1977. ). [PubMed] [Google Scholar]
- 16. ) Bertino , J. R. , Mini , E. and Fernandes , D. J.Sequential methotrexate and 5‐fluorouracil: mechanisms of synergy . Semin. Oncol. , 10 ( Suppl. 2 ), 2 – 5 ( 1983. ). [PubMed] [Google Scholar]
- 17. ) Vogel , S. J. , Presant , C. A. , Ratkin , G. A. and Klahr , C.Phase I study of thymidine plus 5‐fluorouracil infusions in advanced colorectal carcinoma . Cancer Treat. Rep. , 63 , 1 – 5 ( 1979. ). [PubMed] [Google Scholar]
- 18. ) Orem , J. L. and Fischer , P. H.Augmentation of 5‐fluorouracil cytotoxicity in human colon cancer cells by dipyridamole . Cancer Res. , 45 , 2967 – 2972 ( 1985. ). [PubMed] [Google Scholar]
- 19. ) Mitsuya , H. , Weinhold , K. J. , Furman , P. A. , St.Clair , M. H. , Lehrman , S. N. , Gallo , R. C. , Bolognesi , D. , Barry , D. W. and Broder , S.3‐Azido‐3′‐deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T‐lymphotropic virus type III/lymphadenopathy‐associatedvirus invitro.Proc.Natl . Acad. Sci. USA , 82 , 7096 – 7100 ( 1985. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. ) Furman , P. A. , Fyfe , J. A. , St.Clair , M. H. , Weinhold , K. , Rideout , J. L. , Freeman , G. A. , Lehrman , S. N. , Bolognesi , D. P. , Broder , S. , Mitsuya , H. and Barry , D. W.Phosphorylation of 3‐azido‐3‐deoxythymidine and selective interaction of the 5‐triphosphate with human immunodeficiency virus reverse transcriptase . Proc. Natl. Acad. Sci. USA , 83 , 8333 – 8337 ( 1986. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. ) Weber , G. , Nagai , M. , Prajda , N. , Nakamura , H. , Szekeres , T. and Olah , E.AZT: a biochemical response modifier of methotrexate and 5‐fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells . Cancer Commun. , 3 , 127 – 132 ( 1991. ). [DOI] [PubMed] [Google Scholar]
- 22. ) Sano , K. , Sato , F. , Hoshino , T. and Nagai , M.Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR‐antimetabolite continuous regional infusion‐radiation therapy (BAR therapy) . Neural. Med. Chir. , 7 , 51 – 72 ( 1965. ). [DOI] [PubMed] [Google Scholar]
- 23. ) Smith , L. H. , Jr.Pyrimidine metabolism in man . N. Engl J. Med. , 288 , 764 – 771 ( 1973. ). [DOI] [PubMed] [Google Scholar]
- 24. ) Nord , L. D. and Martin , S. D.Loss of murine tumor thymidine kinase activity in vivo following 5‐fluorouracil (FUra) treatment by incorporation of FUra into RNA . Biochem. Pharmacoi , 42 , 2369 – 2375 ( 1991. ). [DOI] [PubMed] [Google Scholar]